MedTrace Logo

Efficacy of CL25216 on Vasomotor Symptoms in Women During Perimenopause

NCT07112651 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2025-12-05

No results posted yet for this study

Summary

This study is to evaluate the effects of CL25216 on vasomotor symptoms in women during Perimenopause. Enrolled subjects will receive either CL25216 - 250 mg/day or placebo.

Conditions

Interventions

DIETARY_SUPPLEMENT

CL25216

250mg to take one capsule a day after breakfast for 105 days

DIETARY_SUPPLEMENT

Placebo

One capsule a day after breakfast for 105 days

Sponsors & Collaborators

  • ApexCPG LLC

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
55 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-11-24
Primary Completion
2026-06-12
Completion
2026-06-12

Countries

  • India

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07112651 on ClinicalTrials.gov